NCT04873752View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

July 12, 2023

Study Completion Date

February 15, 2024

Conditions
Cerebral PalsyPeriventricular Leukomalacia
Interventions
BIOLOGICAL

UDI-001

2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.

Trial Locations (1)

545-8586

Osaka City University Hospital, Osaka

All Listed Sponsors
lead

Rohto Pharmaceutical Co., Ltd.

INDUSTRY